Bridge Bio Eyes Faster Pipeline Progress Through New Funds, Model
This article was originally published in PharmAsia News
A Series A funding for South Korean bioventure Bridge Biotherapeutics may encourage creation of “no research, development only” bioventures and early investments in the biotech sector.
You may also be interested in...
Bridge Biotherapeutics is off to a great start with its recent successful Series A funding, raising the largest amount so far for a South Korean bioventure. The company’s CEO talks to Scrip about where the company is heading including plans for its first-in-class inflammatory bowel disease candidate and further financings.
Amid a boom in IPOs and valuations, experts at a recent forum in Seoul took a look at some of the success factors and challenges behind the rapid growth of South Korea’s bioventure sector.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.